By Brightan Ying
As a PhD candidate, Glyphic Biotechnologies co-founder and CTO Daniel Estandian was puzzled. He saw a clear divide between areas researchers were interested in and the tools that actually existed to explore them. “DNA sequencing has been a hot topic for the past 20 years,” he says. “I found that interesting because biologists I worked with would only talk about proteins. So why isn’t there technology as good as DNA sequencing in the protein space?”
After Daniel met CEO Josh Yang online via Nucleate Bio, the duo decided to create their own answer: Glyphic Bio. “I’ve been working on it for six years. It’s an obvious problem that I find interesting,” Daniel says. “A lot of the people that want to work for Glyphic can also see the clear need for this technology and its profound effects on how we understand biology and treat diseases.”
The road certainly hasn’t been smooth, though. As new founders during a global pandemic, the Glyphic team has faced several unique hurdles. On top of navigating the already treacherous entrepreneurial landscape, they suffered equipment shortages and supply chain issues that made any progress difficult. Daniel remembers asking himself “How do we do science with nothing?”
But now, as he stands on the other side of these challenges, he only feels more ready than ever to tackle whatever comes his way. “When I first started, I kept asking myself ‘am I making the right decisions?’ Eventually, I learned to trust myself and my instincts. It takes a lot to be a founder. Nobody ever finds themselves in that role without a relevant background to be there.”
We couldn’t be more proud of Daniel and Josh’s accomplishments, and are so lucky to have them at Bakar Labs. As members of the LGBTQ+ community, their continued successes help to break down barriers and make the life sciences a more diverse, inclusive field.
Interested in learning more about Glyphic Biotechnologies and what they’re up to now? Click here to check out their company website!